Open an account

Nutra Pharma

NPHC · OTC

$0.0001+$0.00 (+0.00%)TodayMarket closed ·
Prev close $0.0001

About NPHC

Nutra Pharma Corp. operates as a bio pharmaceutical company. The company is headquartered in Plantation, Florida and currently employs 6 full-time employees. The company went IPO on 2001-10-09. The firm's drug candidates include RPI-MN and RPI-78M. RPI-MN is used to treat neurological diseases and autoimmune diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease), Rheumatoid Arthritis (RA) and Myasthenia Gravis. The RPI-78M is used to treat viral diseases, including HIV/AIDS and Herpes. The firm offers Nyloxin/Nyloxin Extra Strength as its over-the-counter (OTC) pain reliever. The company is focused upon marketing homeopathic drugs for the treatment of pain: Nyloxin, Nyloxin Extra Strength Pet Pain, Equine Pain, and Luxury Feet.

Employees
6
Headquarters
Plantation, Florida
Listed
Oct 9, 2001
Sector
Health Care
Industry
Biotechnology
Website
nutrapharma.com

NPHC key statistics

Market cap
715.97K
Price-earnings ratio
0.00
Dividend yield
—
Average volume
310.65K
Volume
928.01K
Open price
$0.0001
High today
$0.0001
Low today
$0.0001
52 Week high
$0.005
52 Week low
$0.00

Nutra Pharma (NPHC) at a glance

Nutra Pharma (NPHC) last traded at $0.0001, with a market cap of 715.97K and a price-to-earnings ratio of 0.00.

Volume so far is 928.01K shares, above the average of 310.65K shares a day.

Over the past year Nutra Pharma has ranged from $0.00 to $0.005, and now sits 2% of the way up that range.

Similar companies

Companies in the same industry as Nutra Pharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.